Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Sickle Cell Disease, Hemoglobinopathies
Interventions: EDIT-301; Genetic
Lead sponsor: Editas Medicine, Inc.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more

Conditions: Sickle Cell Anemia
Interventions: Hydroxyurea, L-Arginine, Sildenafil; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 16 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP)); Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Irvine, California

Conditions: Type 2 Diabetes
Interventions: MOSAIC, Print Materials; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Nashville, Tennessee

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 13 Years and older
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Chronic Periodontitis, Type 2 Diabetes
Interventions: Non-surgical periodontal therapy, Delayed non-surgical periodontal therapy; Procedure · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 35 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Stony Brook, New York + 2 more

Conditions: Pre-Diabetes
Interventions: Functional Ingredient Group, Control Ingredient Group; Dietary Supplement
Lead sponsor: University of Manitoba; Other
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anemia, Healthy, Pediatric ALL
Interventions: Rad-67 Pulse oximeter; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 1 Month and older
Enrollment: 447 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 7
States / cities: Burbank, California • Irvine, California • Lake Forest, California + 3 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: LNP023, Eculizumab, Ravulizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Orange, California • Augusta, Georgia + 2 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: vorinostat; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Anaemia
Interventions: Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 161
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more

Conditions: Sickle Cell Disease
Interventions: Electronic Diary; Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Hollywood, Florida • Upper Marlboro, Maryland • Waltham, Massachusetts + 1 more

Conditions: Physician Workflow, Resource Utilization
Interventions: OPA; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Urethral Stricture, Urethral Diseases
Interventions: Tranexamic Acid, Urethroplasty; Drug · Procedure
Lead sponsor: Amjad Alwaal, MD, MSc, FRCSC, FACS; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: David Grant U.S. Air Force Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Travis Air Force Base, California

Conditions: Weight Loss, Blood Pressure, Lipid Disorder, PreDiabetes, Diabete Mellitus
Interventions: Low-fat plant-based diet; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes
Interventions: Aina HbA1c Monitoring System; Device
Lead sponsor: Jana Care; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Tustin, California • Cambridge, Massachusetts • Methuen, Massachusetts

Conditions: Breast Cancer, Neoplasm Metastasis
Interventions: Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion; Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 2,098 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 14
States / cities: Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more

Conditions: Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
Interventions: HU-Go app; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Years to 25 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anaemia
Interventions: GSK1278863, rhEPO; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 42
States / cities: Paragould, Arizona • Tempe, Arizona • Pine Bluff, Arkansas + 34 more

Conditions: Sickle Cell Disease
Interventions: Hydroxyurea; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 15 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus
Interventions: Diabetes Outcome; Diagnostic Test
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 80 Years
Enrollment: 34,121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anemia
Interventions: Not listed
Lead sponsor: Convergence Biometrics; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions: Canagliflozin (JNJ-28431754), Sitagliptin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more

Search by objective public record fields.

A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia

Accuracy of Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI)

MObile Support Adapted to Individual Contexts

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

Diabetes and Periodontal Therapy Trial

Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes

Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

A Study to Learn About Sickle Cell Disease In Adult Patients

Evaluating a Our Practice Advisory (OPA) to Optimize Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) Test Orders

REDUCER Trial (TXA in Urethroplasty)

Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus

Feasibility & Implementation of a Plant-Based Weight-Loss Program in an Office-Based Setting

Reproducibility of HbA1c Measurement on the Aina HbA1c Monitoring System

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

Walnut Consumption and Diabetes Risk

Non-Invasive Hemoglobin Study

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes